Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    NIAID Funds $9.4M for Next-Gen Anthrax Vaccine

    By Stephanie LizotteJanuary 3, 2012
    Sterne Bacillus Anthracis - Anthrax Culture
    Image credit: Todd Parker/CDC
    Share
    Facebook LinkedIn Reddit Email

    Biopharmaceutical company Soligenix, through an agreement with Harvard University, will be working towards a next-generation single-dose anthrax vaccine under a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant.

    Soligenix received an exclusive option agreement with Harvard University to cover prophylactic uses of a modified anthrax protective antigen (PA) developed in the Harvard Medical School laboratory of Dr. John Collier.

    The option encompasses an issued U.S. patent that covers engineered variants of PA which is the principal determinant of protective immunity to anthrax. Soligenix believes that it will be able to develop the Collier anthrax vaccine with an efficacy profile superior to other anthrax vaccines and with a more stable shelf-life.

    “We believe that the engineered PA variants can be used in platform technologies for delivery of single use or combination biodefense vaccines and will be useful for generating stable vaccines that induce antibodies in fewer doses than the conventional AVA or other rPA vaccines currently under development,” stated Christopher J. Schaber, PhD, President and CEO of Soligenix. “Another significant improvement for stockpiled vaccines we intend to focus on would be extended stability relative to conventional vaccines. If long-term stability were achieved, the vaccine would have the potential to be stockpiled for general use and for post-exposure prophylaxis.”

    The company further envisions expanding their thermostability technology into development of countermeasures against more common infectious diseases.

    Anthrax Bioterrorism NIAID NIH Strategic National Stockpile Thermostability Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleAir Force BAA for Advances in Biosciences
    Next Article NIAID Seeks Non-Human Primate Lab Testing Services

    Related Stories

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.